FAM225A and gastric cancer: Clinicopathological analysis indicated that increased expression of FAM225A was associated with a higher lymph node metastasis rate, larger tumor size, and more advanced tumor stage, and the increased expression of FAM225A indicated poor prognosis in GC patients.